Preventing RSV in infants born in France during the 2024–2025 season

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will use a questionnaire of mothers who deliver term infants in metropolitan France between October 1, 2024 and January 31, 2025 to document which RSV prevention measures their newborns receive and to identify barriers to uptake. Participants must be at least 18 years old, able to read and understand French, have a live term newborn, and not be under legal protection. The observational design collects self-reported data at participating sites including Hôpital Pitié Salpêtrière and public health departments without introducing any interventions. Results will describe national coverage of newer pharmacological options (for example nirsevimab and forthcoming vaccines) alongside existing non-pharmacological measures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18
* Able to speak and understand French well enough to read and comprehend the information leaflet and the questionnaire
* Delivery in metropolitan France between October 1, 2024, and January 31, 2025
* Live-born child
* Term-born child (37 weeks of gestation or more)
* No objection to participating in the study

Exclusion Criteria:

* Women under legal protection

Where it's running

• Public health department, Hôpital Pitié Salpêtrière
  Paris, France Recruiting

Study contacts

• Study coordinator: Bénédicte COULM, RM,PhD
• Email: benedicte.coulm@aphp.fr
• Phone: 01 84 82 85 34

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zelicapavir for RSV infection in young children

  This study tests whether Zelicapavir can help treat RSV infection in children aged 28 days to 36 months who are showing symptoms.

  Recruiting at 8 sites Phase 2 Enanta Pharmaceuticals, Inc · Bangkok and 7 other locations · NCT07482657

• Revaccination with RSV vaccine during subsequent pregnancies

  This study is testing if giving a second dose of the RSV vaccine to pregnant women who already had it is safe and effective for them and their babies.

  Recruiting at 96 sites Phase 3 Pfizer · Birmingham, Alabama and 96 other locations · NCT06866405

• Revaccination with SCB-1019T vaccine in older adults

  This study is testing a new vaccine called SCB-1019T to see if it can boost immunity in healthy adults aged 60-85 who have already received the AREXVY vaccine.

  Recruiting at 5 sites Phase 1 Clover Biopharmaceuticals, Ltd · Phoenix, Arizona and 4 other locations · NCT06843317

• Vaccination against RSV in patients with weakened immune systems

  This study tests if giving two doses of the RSV vaccine to patients with weakened immune systems helps them better fight off RSV infections compared to the standard one dose given to healthy older adults.

  Recruiting Phase 2 Medical University of Vienna · Vienna · NCT06597916

• Evaluating the effectiveness of RSV vaccines in real-world settings

  This study is testing how well RSV vaccines work in the real world for infants who get respiratory illnesses.

  Recruiting Yale University · New Haven, Connecticut · NCT06172660

• Measuring how RSV affects young children seen in clinics and hospitals

  This project will test adding lab tests for RSV, flu, and COVID-19 for children under 2 who come to clinics or hospitals with ear infections or bronchiolitis to see how often RSV causes their illness.

  Recruiting Association Clinique Thérapeutique Infantile du val de Marne · Créteil · NCT04743609

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.